How India Exports Guaifenesin to the World

In the United States, Guaifenesin is approved for over-the-counter (OTC) use, allowing consumers to purchase it without a prescription. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Guaifenesin, indicating a competitive generic market. Notably, there have been recent approvals, such as the ANDA granted to [Company Name] in January 2026. Importantly, as of March 2026, there are no active FDA import alerts specifically targeting Guaifenesin products from India, suggesting compliance with US regulatory standards.

The substantial number of Indian exporters—151 active between 2022 and 2026—underscores India's pivotal role in supplying Guaifenesin to the US market. This extensive exporter base reflects the robust demand and the competitive landscape within the United States.

In the European Union, Guaifenesin is subject to marketing authorization requirements overseen by the European Medicines Agency (EMA). While specific EMA actions regarding Guaifenesin are not detailed in the available data, manufacturers must adhere to the EU's Good Manufacturing Practice (GMP) guidelines to ensure product quality and safety.

Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates Guaifenesin. Compliance with UK GMP standards is mandatory for market authorization. As of March 2026, there have been no significant regulatory actions or updates concerning Guaifenesin reported by the MHRA.

Guaifenesin is not listed on the World Health Organization's (WHO) Model List of Essential Medicines as of the 24th edition published in September 2025. This exclusion indicates that, while beneficial, Guaifenesin is not considered essential for addressing priority health care needs globally.

Regarding pharmacopoeial standards, Guaifenesin is included in major compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These inclusions provide standardized quality benchmarks for its production and quality control.

In India, Guaifenesin is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for its sale. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on Guaifenesin, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations.

Guaifenesin's primary patents have expired, leading to a competitive generic market with multiple manufacturers producing the drug. This patent expiration has facilitated the entry of numerous generic versions, enhancing accessibility and affordability.

In August 2025, the NPPA conducted a review of Guaifenesin's market prices to assess affordability, though no price controls were implemented. In October 2025, the CDSCO issued updated guidelines for the export of pharmaceutical products, emphasizing stringent quality checks, which directly impact Guaifenesin exporters. Additionally, in December 2025, the WHO released the 24th edition of its Model List of Essential Medicines, reaffirming the exclusion of Guaifenesin.

These developments highlight the dynamic regulatory environment affecting Guaifenesin's production, pricing, and exportation.

India's pharmaceutical industry, including the production of guaifenesin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of APIs used in Indian pharmaceutical manufacturing are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade disputes, or regulatory changes in China.

In response to this vulnerability, the Indian government has implemented the Production Linked Incentive (PLI) scheme to bolster domestic manufacturing of critical KSMs and APIs. As of March 2025, the scheme has led to an investment of ₹4,570 crore, surpassing the initial commitment of ₹3,938.5 crore over six years. This initiative has resulted in import savings of ₹1,362 crore by March 2025, indicating progress toward reducing dependency on foreign sources. However, the effectiveness of these measures in fully mitigating supply chain risks remains to be seen.

Our proprietary trade data reveals that the top five Indian exporters of guaifenesin account for 62.8% of total exports, with Granules India Limited leading at a 35.4% share. This high concentration indicates a significant single-source risk, as disruptions affecting these key suppliers could substantially impact the global supply chain.

The PLI scheme aims to diversify and strengthen domestic production capabilities. By March 2025, the scheme had facilitated the creation of domestic manufacturing capacity for 25 identified KSMs, DIs, and APIs, contributing to reduced import dependence. While these efforts are commendable, the current supplier concentration necessitates continued vigilance and strategic planning to mitigate potential risks associated with reliance on a limited number of exporters.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt maritime transport. Such disruptions can delay shipments of guaifenesin and its raw materials, leading to supply shortages. Additionally, ongoing U.S.-China trade tensions may impact the availability and cost of APIs and KSMs sourced from China, further exacerbating supply chain vulnerabilities.

Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have previously issued alerts regarding drug shortages linked to supply chain disruptions. While specific alerts for guaifenesin are not currently reported, the interconnected nature of pharmaceutical supply chains means that disruptions in one area can have cascading effects, potentially leading to shortages and increased costs.

• Diversify Supplier Base: Encourage the development of additional domestic manufacturers for guaifenesin to reduce reliance on a limited number of exporters.

• Enhance Domestic Production: Continue to support and expand initiatives like the PLI scheme to strengthen domestic API and KSM manufacturing capabilities.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events that could impact key shipping routes and implement contingency plans accordingly.

• Strengthen Regulatory Compliance: Ensure that domestic manufacturers adhere to international quality standards to prevent regulatory actions that could disrupt exports.

• Develop Strategic Reserves: Create stockpiles of critical APIs and KSMs to buffer against potential supply chain disruptions.

RISK_LEVEL: MEDIUM